Published in JAMA on March 12, 2006
Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis. Coron Artery Dis (2014) 1.60
Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. J Am Coll Cardiol (2008) 1.55
Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol (2008) 1.18
Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol (2011) 0.88
Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent. J Zhejiang Univ Sci B (2010) 0.84
Sirolimus-eluting coronary stents: a review. Vasc Health Risk Manag (2007) 0.83
Everolimus-eluting stents in interventional cardiology. Vasc Health Risk Manag (2012) 0.80
Treatment of coronary in-stent restenosis-evidence for universal recommendation? J Thorac Dis (2015) 0.79
Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry. Clin Res Cardiol (2008) 0.79
A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis. Int J Cardiol (2007) 0.79
Drug eluting balloons for the treatment of coronary artery disease: What can we expect? World J Cardiol (2010) 0.78
Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel. J Transl Med (2008) 0.78
Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents. J Tehran Heart Cent (2013) 0.78
Treatment of in-stent restenosis with excimer laser coronary angioplasty: benefits over scoring balloon angioplasty alone. Lasers Med Sci (2016) 0.77
Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis. Catheter Cardiovasc Interv (2010) 0.77
Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease. Clin Res Cardiol (2012) 0.77
Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry. Clin Res Cardiol (2009) 0.75
Brachytherapy for in-stent restenosis: a distant second choice to drug-eluting stent placement. JAMA (2006) 0.75
Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis. Am Heart J (2007) 0.75
Sirolimus-eluting stents vs brachytherapy for restenosis. JAMA (2006) 0.75
Clinical presentation and predictors of target vessel revascularization after drug-eluting stent implantation. Cardiovasc Revasc Med (2012) 0.75
Techniques in Vascular and Interventional Radiology Drug Delivery Technologies in the Superficial Femoral Artery. Tech Vasc Interv Radiol (2016) 0.75
Long-term angiographic outcomes of post-sirolimus-eluting stent restenosis in Japanese patients. Heart Vessels (2010) 0.75
Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol (2017) 0.75
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med (2004) 12.58
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A (2003) 7.14
The metabolic syndrome. Endocr Rev (2008) 5.33
Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med (2008) 4.72
Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet (2008) 4.17
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Abnormal cerebral structure is present at term in premature infants. Pediatrics (2005) 3.81
Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell (2009) 3.69
A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4. Nat Genet (2010) 3.63
Comparative analysis of a large dataset indicates that internal transcribed spacer (ITS) should be incorporated into the core barcode for seed plants. Proc Natl Acad Sci U S A (2011) 3.41
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med (2013) 3.27
Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem (2002) 3.02
Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation (2010) 2.88
Correlates of axial gout: a cross-sectional study. J Rheumatol (2012) 2.86
Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology (2015) 2.81
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst (2006) 2.79
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol (2004) 2.78
Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis (2010) 2.64
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA (2008) 2.59
A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol (2005) 2.56
Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation (2002) 2.53
Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med (2002) 2.52
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 2.52
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell (2009) 2.50
Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol Rev (2007) 2.46
Local, persistent activation of Rho GTPases during plasticity of single dendritic spines. Nature (2011) 2.42
Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation (2004) 2.35
A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31
Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med (2003) 2.30
Local determinants of thrombus formation following sirolimus-eluting stent implantation assessed by optical coherence tomography. JACC Cardiovasc Interv (2009) 2.29
Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation (2004) 2.29
A genomic atlas of mouse hypothalamic development. Nat Neurosci (2010) 2.25
Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv (2009) 2.24
IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol (2003) 2.24
The reporting of blinding in physical medicine and rehabilitation randomized controlled trials: a systematic review. J Rehabil Med (2013) 2.20
Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation (2009) 2.19
Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med (2011) 2.18
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol (2007) 2.17
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv (2009) 2.12
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med (2010) 2.08
Three-year outcomes of vaginal mesh for prolapse: a randomized controlled trial. Obstet Gynecol (2013) 2.08
Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol (2004) 2.05
Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res (2007) 2.04
Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the Strong Heart Study. J Clin Hypertens (Greenwich) (2011) 2.04
Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation (2003) 2.04
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA (2006) 2.03
The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med (2003) 2.00
C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. Mol Cell Biol (2009) 1.98
Prostaglandin E2 mediates connecting tubule glomerular feedback. Hypertension (2013) 1.98
Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum (2010) 1.98
Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation (2004) 1.96
Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol (2006) 1.95
Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res (2006) 1.95
Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol (2002) 1.93
In vivo comparison between optical coherence tomography and intravascular ultrasound for detecting small degrees of in-stent neointima after stent implantation. JACC Cardiovasc Interv (2008) 1.91
Medical device development: from prototype to regulatory approval. Circulation (2004) 1.90
Tanycytes of the hypothalamic median eminence form a diet-responsive neurogenic niche. Nat Neurosci (2012) 1.89
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med (2012) 1.87
An essential role for stromal interaction molecule 1 in neointima formation following arterial injury. Cardiovasc Res (2008) 1.87
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2008) 1.85
Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol (2013) 1.85
A group of glutamatergic interneurons expressing high levels of both neurokinin-1 receptors and somatostatin identifies the region of the pre-Bötzinger complex. J Comp Neurol (2003) 1.85
Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci (2007) 1.85
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res (2006) 1.83
Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation (2004) 1.83
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol (2010) 1.80
PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J Biol Chem (2003) 1.77
Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice. Blood (2011) 1.77
A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous coronary intervention (The PROTECT I Trial): initial U.S. experience. JACC Cardiovasc Interv (2009) 1.76
Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation (2004) 1.72
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One (2008) 1.72
Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension (2006) 1.71
Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A (2007) 1.71
Ethnic differences in the treatment of depression in patients with ischemic heart disease. Am Heart J (2008) 1.70
Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv (2009) 1.70
Novel index for invasively assessing the coronary microcirculation. Circulation (2003) 1.69
Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation (2005) 1.67
Consequences of lipid droplet coat protein downregulation in liver cells: abnormal lipid droplet metabolism and induction of insulin resistance. Diabetes (2008) 1.65
Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25-30 months. Clin Endocrinol (Oxf) (2010) 1.63
The financial protection effect of Ghana National Health Insurance Scheme: evidence from a study in two rural districts. Int J Equity Health (2011) 1.63
Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J Biol Chem (2008) 1.62
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol (2002) 1.62
Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation (2002) 1.61